Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Lawrence

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
The Lancet. Global Health|April 27, 2025
Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trialsThomas H A Samuels, Sile F Molloy, David S Lawrence, et al.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
The Lancet. HIV|October 6, 2023
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation studySayoki Mfinanga, Cecilia Kanyama, Charles Kouanfack, et al.
Journal of the International AIDS Society|June 6, 2025
Household economic impact of HIV-associated cryptococcal meningitis in five countries in Southern and Eastern AfricaDavid S Lawrence, Charles Muthoga, Jack Adams, et al.
The Lancet. Global Health|November 18, 2022
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trialDavid S Lawrence, Charles Muthoga, David B Meya, et al.
The New England Journal of Medicine|March 23, 2022
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal MeningitisJoseph N Jarvis, David S Lawrence, David B Meya, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
The Lancet. Global Health|April 27, 2025
Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trialsThomas H A Samuels, Sile F Molloy, David S Lawrence, et al.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
The Lancet. HIV|October 6, 2023
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation studySayoki Mfinanga, Cecilia Kanyama, Charles Kouanfack, et al.
Journal of the International AIDS Society|June 6, 2025
Household economic impact of HIV-associated cryptococcal meningitis in five countries in Southern and Eastern AfricaDavid S Lawrence, Charles Muthoga, Jack Adams, et al.
The Lancet. Global Health|November 18, 2022
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trialDavid S Lawrence, Charles Muthoga, David B Meya, et al.
The New England Journal of Medicine|March 23, 2022
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal MeningitisJoseph N Jarvis, David S Lawrence, David B Meya, et al.
Pageof 16